Skip to main content

Table 4 Presumptive causative pathogens in the two treatment groups

From: Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial

n = 124
n = 139
Streptococcus pneumoniae35 (10)26 (1)
Haemophilus influenzae3 (1)3
Klebsiella pneumoniae03
Enterobacter cloacae01
Pseudomonas aeruginosa03
Moraxella catarrhalis2 (1)1
Mycoplasma pneumoniae38 (10)28 (1)
Chlamydophila pneumoniae04
  1. CTRX Ceftriaxone, ABPC/SBT Ampicillin/sulbactam, MSSA Methicillin-sensitive Staphylococcus aureus. The number of cases with other pathogens detected is indicated in parentheses. Sputum examinations were not possible in 58 cases of the CTRX group and 69 cases of the ABPC/SBT group (p = 0.711). Missing data were in three patients of the CTRX group vs in seven of the ABPC/SBT group for blood culture examination (p = 0.343), one vs one for Mycoplasma pneumoniae and Chlamydophila pneumoniae antibody tests (p = 1.000), 22 vs 19 for urinary antigen tests of Streptococcus pneumoniae and Legionella pneumophilia serogroup 1 (p = 0.398). *Diagnosed by influenza virus antigen using throat or nasal swab specimens